|
| Friday, 29 January 2021, 08:00 HKT/SGT | |
| |
|
|
|
|
| The research demonstrated that the OX40 design enhanced the antitumor activity of CAR-T cells with the potential to overcome the challenge of treating solid tumors |
HONG KONG, Jan 29, 2021 - (ACN Newswire) - China Biotech Services Holdings Limited ("CH BIOTECH SER" or "Company", stock code: 8037.HK) non-wholly-owned subsidiary Shanghai Longyao Biotechnology Co., Ltd. ( "Shanghai Longyao"), the Chief Scientist Professor Xuanming Yang published a CD20-CART-OX40 related research article on January 27, 2021, EST, on Science Translational Medicine. Professor Yang found that an independently expressed full-length OX40 not only enhanced the cytotoxicity of CAR-T cells, it also reduced the exhaustion markers, thereby maintaining their function in immunosuppressive tumor microenvironment. In mouse tumor models and in patients with metastatic lymphoma, these CAR-T cells exhibited robust amplification and antitumor activities. The findings provide an alternative option for CAR-T optimization with the potential to overcome the challenge of treating solid tumors.
LY007 Cellular Injection is a chimeric antigen receptor T-cell (CAR-T) injection and is mainly used in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and metastatic follicular lymphoma. LY007 Cellular Injection has been developed independently by Shanghai Longyao and incorporates its patented OX40 co-stimulatory signal design. Experiments have proved that the design enhances the efficacy of the Product without compromising safety. According to the clinical trial application of LY007 Cellular Injection, Shanghai Longyao will commence Phase I clinical trial and study of LY007 Cellular Injection based on the submitted proposal. On January 21, 2021, the National Medical Products Administration's approval of Shanghai Longyao's clinical trial application for LY007 Cellular Injection demonstrates Shanghai Longyao's capabilities in the research and development of immunocellular drugs.
For further information about the CD-20-CART-OX40 related research article of Professor Yang Xiaoming, please visit the website of Science Translational Medicine https://stm.sciencemag.org/content/13/578/eaba7308
Topic: Press release summary
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| |
Latest Press Releases
Hola Prime and Pro Basketball Player Karl-Anthony Towns Team up for 'Speed is Success' Campaign, Redefining Prop Trading 
May 14, 2025 22:20 HKT/SGT
|
|
|
Business delegation concludes Middle East mission in Kuwait
May 14, 2025 21:37 HKT/SGT
|
|
|
Quotient Capital's Strategic Outlook for 2025
May 14, 2025 19:45 HKT/SGT
|
|
|
Staying Ahead in the Digital Era as AI Takes Full Center Stage at InfoComm Asia 2025 -- Visitor Registration Opens
May 14, 2025 18:29 HKT/SGT
|
|
|
MHI Starts Operation of New CO2 Capture Pilot Plant at KEPCO's Himeji No.2 Power Station
Wednesday, May 14, 2025 3:50:00 PM
|
|
|
Southeast Asian stem cell leader Medeze launches voluntary conditional cash partial offer for 10% stake in SGX-listed Cordlife Group Limited
May 14, 2025 15:00 HKT/SGT
|
|
|
Making Anime More Interesting and Taking it into the Future, Launch of Three New Projects
Wednesday, May 14, 2025 10:00:00 AM
|
|
|
OMP's Unison Planning Achieves SAP(R) Certified Integration with RISE with SAP S/4HANA(R) Cloud
May 13, 2025 19:00 HKT/SGT
|
|
|
Widespread Use Of Illicit Streaming Devices In Taiwan Poses Potential National Cybersecurity Threat, New Research Finds
May 13, 2025 17:05 HKT/SGT
|
|
|
EdgePoint completes 12 projects under its Connectivity for Communities Program, impacting more than 6,500 students across Malaysia, Indonesia and the Philippines
May 13, 2025 15:00 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
